Abstract: The disclosed embodiments are generally directed to improving feature detection of rapidly acquired images using camera-enabled mobile devices involving a 2-D decal code, such as a QR code, for improving the reading accuracy of a rapid diagnostic antigen or antibody or enzymatic colorimetric directed test, such as for COVID-19 diagnosis. One primary issue with evaluating a Covid-19 rapid test is detecting and quantifying positive test lines from sampled test strips based on digital images of the test strip. Aspects of the present invention contemplate masking a QR code to improve the sample image resolution and contrast. Other aspects of the present invention contemplate methods and techniques to evaluate a test line on the sample image by enhancing an intensity curve along the test line and control line containing area by way of calculating the instantaneous change in pixel intensity and evaluating the position and intensity of those signals.

Abstract: The disclosed embodiments are generally directed to improving feature detection of rapidly acquired images using camera-enabled mobile devices involving a 2-D decal code, such as a QR code, for improving the reading accuracy of a rapid diagnostic antigen or antibody or enzymatic colorimetric directed test, such as for COVID-19 diagnosis. One primary issue with evaluating a Covid-19 rapid test is detecting and quantifying positive test lines from sampled test strips based on digital images of the test strip. Aspects of the present invention contemplate masking a QR code to improve the sample image resolution and contrast. Other aspects of the present invention contemplate methods and techniques to evaluate a test line on the sample image by enhancing an intensity curve along the test line and control line containing area by way of calculating the instantaneous change in pixel intensity and evaluating the position and intensity of those signals.

Abstract: The disclosed embodiments are generally directed to improving feature detection of rapidly acquired images using camera-enabled mobile devices involving a 2-D decal code, such as a QR code, for improving the reading accuracy of a rapid diagnostic antigen or antibody or enzymatic colorimetric directed test, such as for COVID-19 diagnosis. One primary issue with evaluating a Covid-19 rapid test is detecting and quantifying positive test lines from sampled test strips based on digital images of the test strip. Aspects of the present invention contemplate masking a QR code to improve the sample image resolution and contrast. Other aspects of the present invention contemplate methods and techniques to evaluate a test line on the sample image by enhancing an intensity curve along the test line and control line containing area by way of calculating the instantaneous change in pixel intensity and evaluating the position and intensity of those signals.

Abstract: The disclosed embodiments are generally directed to improving feature detection of rapidly acquired images using camera-enabled mobile devices involving a 2-D decal code, such as a QR code, for improving the reading accuracy of a rapid diagnostic antigen or antibody or enzymatic colorimetric directed test, such as for COVID-19 diagnosis. One primary issue with evaluating a Covid-19 rapid test is detecting and quantifying positive test lines from sampled test strips based on digital images of the test strip. Aspects of the present invention contemplate masking a QR code to improve the sample image resolution and contrast. Other aspects of the present invention contemplate methods and techniques to evaluate a test line on the sample image by enhancing an intensity curve along the test line and control line containing area by way of calculating the instantaneous change in pixel intensity and evaluating the position and intensity of those signals.

Abstract: One of the main problems with introducing target therapeutics and diagnostic biomarkers (Target substances) into the brain is the nearly impenetrable blood brain barrier. Some of the proposed described solutions to mobilizing these target therapeutics and markers into select areas of the brain include nano-particles and nano-capsules containing at least one of the target substances with exposed cannabinoid functional end groups that can selectively facilitate nano-capsule traversal across the blood brain barrier into brain tissue. In this way, the target substances can reach their intended target within the brain to either treat or identify regions of pathology. Certain concepts described involve nano/micro-particles with exposed cannabinoid functional end groups extending beyond the surface of the nano-particles.

Abstract: Embodiments described are generally directed to a test sample apparatus. The test sample apparatus generally comprises a holder base arranged that accommodates a tablet or cell phone. The apparatus has a hood that is placed over a portion of the tablets illuminating touchscreen such that the illuminating touchscreen provides light that can be collected by the hood. There is a chamber integrated with the hood adapted to accommodate a chemically activated test strip. The chemically activated test strip is illuminated when the hood collects light from the illuminating touchscreen. A lens in the hood interposed between the camera and the test strip enables the camera to focus on a portion of the chemically activated test strip when the hood is placed over the portion of the illuminating touchscreen.

Abstract: Embodiments described are generally directed to a test sample apparatus. The test sample apparatus generally comprises a holder base arranged that accommodates a tablet or cell phone. The apparatus has a hood that is placed over a portion of the tablets illuminating touchscreen such that the illuminating touchscreen provides light that can be collected by the hood. There is a chamber integrated with the hood adapted to accommodate a chemically activated test strip. The chemically activated test strip is illuminated when the hood collects light from the illuminating touchscreen. A lens in the hood interposed between the camera and the test strip enables the camera to focus on a portion of the chemically activated test strip when the hood is placed over the portion of the illuminating touchscreen.

Abstract: Embodiments described are generally directed to a method for applying a composition for managing dysallostasis effects to cannabinoids from repeated administration. The method envisions providing an anti-dysallostatic composition essentially comprised of a combination of phytoterpenoid and phytocannabinoid plus an independently derived phytoterpenoid that is between 70% and 95%, the phytocannabinoid includes THC and CBD. A dose of the composition is introduced to a subject sublingually while in a state of dysallostasis from prior consumption of the THC, the dose is approximately 5 mg of the THC, 1.25 mg of the CBD and 0.3-0.6 mg of the phytoterpenoid and between approximately 0.3-2.0 mg of the independently derived phytoterpenoid. The dose is increased if there is a change from the state of dysallostasis to two doses at a time interval, but if there is not a change from the state of dysallostasis, increasing administration of the composition sublingually to 3 doses at the predetermined interval.

Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In certain embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol, cannabidiol and, optionally, terpenes such as linalool.

Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.

Abstract: Embodiments described are generally directed to a test sample apparatus. The test sample apparatus generally comprises a holder base arranged that accommodates a tablet or cell phone. The apparatus has a hood that is placed over a portion of the tablets illuminating touchscreen such that the illuminating touchscreen provides light that can be collected by the hood. There is a chamber integrated with the hood adapted to accommodate a chemically activated test strip. The chemically activated test strip is illuminated when the hood collects light from the illuminating touchscreen. A lens in the hood interposed between the camera and the test strip enables the camera to focus on a portion of the chemically activated test strip when the hood is placed over the portion of the illuminating touchscreen.

Abstract: A cannabis plant extract based formulation to aid in stabilizing the therapeutic efficacy of cannabinoid containing treatments in patients affected with neurological diseases that comprises one or more of the following: Cannabidiol (CBD), tetrahydrocannabinol (THC), and terpenes; wherein the formulation comprises a high ratio of CBD to THC, with each of those cannabinoids in a relatively high concentration. The formulation also comprises Beta-caryophyllene that is used to further aid in neuroprotection by co-modulating CB1 and 2 receptors. Additionally, the formulation comprises the terpene humulene to assist in creating an “entourage effect” in conjunction with CBD, THC, and Beta-caryophyllene to stabilize and enhance treatment-related pharmacological actions. The formulation may also comprise Cannabichromene (CBC), Cannabigerol (CBG), and Cannabinol (CBN).

Abstract: Embodiments described are generally directed to a test sample apparatus. The test sample apparatus generally comprises a holder base arranged that accommodates a tablet or cell phone. The apparatus has a hood that is placed over a portion of the tablets illuminating touchscreen such that the illuminating touchscreen provides light that can be collected by the hood. There is a chamber integrated with the hood adapted to accommodate a chemically activated test strip. The chemically activated test strip is illuminated when the hood collects light from the illuminating touchscreen. A lens in the hood interposed between the camera and the test strip enables the camera to focus on a portion of the chemically activated test strip when the hood is placed over the portion of the illuminating touchscreen.

Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.

Abstract: Embodiments described are generally directed to a test sample apparatus. The test sample apparatus generally comprises a holder base arranged that accommodates a tablet or cell phone. The apparatus has a hood that is placed over a portion of the tablets illuminating touchscreen such that the illuminating touchscreen provides light that can be collected by the hood. There is a chamber integrated with the hood adapted to accommodate a chemically activated test strip. The chemically activated test strip is illuminated when the hood collects light from the illuminating touchscreen. A lens in the hood interposed between the camera and the test strip enables the camera to focus on a portion of the chemically activated test strip when the hood is placed over the portion of the illuminating touchscreen.